Parallel importer sees market for Novo Nordisk obesity drug in new countries

According to CEO Flemming Wagner, Abacus Medicine is looking into the possibility of parallel importing Novo Nordisk’s coveted obesity drug, Wegovy. 
Flemming Wagner, adm. direktør hos parallelimportøren Abacus Medicine. | Photo: Pr / Abacus
Flemming Wagner, adm. direktør hos parallelimportøren Abacus Medicine. | Photo: Pr / Abacus

There may be opportunities in Novo Nordisk’s limited launches of popular obesity drug Wegovy (semaglutide) in Europe, Flemming Wagner, CEO of parallel importer Abacus Medicine, tells Finans

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading